Viatris Inc. (NASDAQ: VTRS, “Viatris” or the “Company”) today announced the early results of its subsidiary Utah Acquisition Sub Inc.’s (“UAS”) previously announced cash tender offer (the “Maximum Tender Offer”). UAS has increased the maximum aggregate principal amount for the…
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), an AI-driven biotherapeutics research and technology company, has announced its financial results for the first quarter of fiscal 2025, ending on July 31, 2024. All figures are reported in Canadian dollars (CAD) unless stated otherwise.…
Tempus AI, Inc. (NASDAQ: TEM), a leader in advancing precision medicine through AI technology, has announced that four of its abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024, taking place in Barcelona,…
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and sa-mRNA pioneer Arcturus Therapeutics have announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved their updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®. This vaccine is designed to protect adults 18…
Sanofi has entered into an exclusive licensing agreement with RadioMedix, Inc., a U.S.-based biotechnology company developing radiopharmaceuticals for PET imaging and targeted alpha therapy (TAT), and Orano Med, a French subsidiary of the Orano Group focused on lead-212 (212Pb) radioligand…
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced that BOTOX® Cosmetic (onabotulinumtoxinA) is now available in China for the treatment of masseter muscle prominence (MMP). The masseter muscle, located in the lower face, is involved in chewing, and…
Xencor, Inc. (Nasdaq: XNCR), a clinical-stage biopharmaceutical company focused on developing engineered antibodies for treating cancer and other serious conditions, has announced the launch of an underwritten public offering of its common stock. Certain investors may choose to purchase pre-funded…
Ncardia, a leading human iPSC company, has announced the launch of a new panel of ready-to-use assays aimed at streamlining the screening and selection of therapeutic candidates, with a particular focus on neurodegenerative diseases. This innovative panel offers standardized, robust,…
enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company, announced its financial results for the third quarter ending July 31, 2024, along with a business update. The company’s lead investigational product, detalimogene voraplasmid (formerly known as EG-70), is currently…
Ascendis Pharma A/S (Nasdaq: ASND) has released its financial results for the second quarter, which ended on June 30, 2024, alongside a business update. “The recent FDA approval of YORVIPATH underscores our commitment to helping patients with hypoparathyroidism and other…
Eli Lilly and Company (NYSE: LLY) has announced positive results from two phase 3 clinical trials, QWINT-1 and QWINT-3, evaluating once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes. The trials assessed efsitora’s efficacy in individuals starting insulin…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced the results from its Phase 3 PALISADE study, which investigated the efficacy of the drug plozasiran in patients with familial chylomicronemia syndrome (FCS). FCS is a rare and severe genetic condition that currently…
